Mucopolysaccharidosis I, Mucopolysaccharidosis II, Mucopolysaccharidosis VI
Conditions
Brief summary
Randomized, double-blind, placebo-controlled, parallel-group, single-center study followed by open-label phase, to evaluate the effects of adalimumab compared to placebo on the change from baseline in joint and skeletal disease in children and adults with mucopolysaccharidosis (MPS) I, II or VI.
Detailed description
This study is a randomized, double-blind, placebo-controlled, parallel-group, single-center study followed by open-label phase, to evaluate the effects of adalimumab compared to placebo on the change from baseline in joint and skeletal disease in children and adults with mucopolysaccharidosis (MPS) I, II or VI. Children and adults diagnosed with MPS I, II or VI, with significant joint restrictions and pain will be randomized to adalimumab treatment or placebo treatment for the first 16 weeks. This will be followed by a 32-week open label adalimumab treatment phase.
Interventions
DRUGAdalimumab Injection [Humira]
Investigational Drug
Placebo Comparator
Sponsors
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
McGill University Health Centre/Research Institute of the McGill University Health Centre
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
5 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female ≥5 years of age; * Diagnosis of MPS I, II or VI; * Treatment with ERT for ≥1 year or no treatment with ERT for ≥1 year; * Weight ≥15 kg; * Significant bodily pain reported by the CHQ-PF50 or SF-36 (\> 1 SD more severe \[below\] than the general population mean); * ≥ 3 joints with limitations in motion; and Patient or parent/legal guardian is able and willing to provide informed consent. For patients 7 to 17 years of age, assent must also be provided.
Exclusion criteria
* History of HCT less than 2 years prior to enrollment; * Immune suppression therapy less than 1 year prior to enrollment; * Active graft versus host disease; * Current diagnosis or history of lymphoma or other malignancy; * Current active infection; * History of serious opportunistic infection (e.g., bacterial \[Legionella and Listeria\]; tuberculosis \[TB\]; invasive fungal infections; or viral, parasitic, and other opportunistic infections); * Positive TB skin test, positive Quantiferon-TB Gold TB test, positive chest X-ray, or a recent exposure to TB * Congestive heart failure defined by an ejection fracture \<50% measured by ECHO; * Demyelinating disorders (e.g., central nervous system \[CNS\] disorders including multiple sclerosis and optic neuritis and peripheral nervous system disorders including Guillain-Barre syndrome); * Hematologic abnormalities (e.g., pancytopenia, aplastic anemia); * Hepatitis B infection (active or chronic carrier); * Latex sensitivity; * Pregnancy or breastfeeding; * Known or suspected allergy to adalimumab or related products; * Participation in simultaneous therapeutic study that involves an investigational study drug or agent within 4 weeks of study enrollment; * Requirement for live vaccine exposure that would be expected to occur during the time frame of the study; or * Any other social or medical condition that the Investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated or be detrimental to the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Pain - 16 weeks | 16 weeks | Mean difference in bodily pain measured by the Children's Health Questionnaire - Parent Form 50 (CHQ-PF50) or the Medical Outcomes Study - Short Form 36 (SF-36) in treatment versus placebo at 16 weeks |
| Adalimumab trough | 32 weeks | Percentage of subjects who achieve a goal trough concentration of adalimumab with every other week dosing |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Joint range-of-motion - 16 weeks | 16 weeks | Percentage of subjects who achieve a 5 degree or more improvement in joint range-ot-motion in treatment versus placebo at 16 weeks. |
| Pain - 52 weeks | 52 weeks | Mean difference in bodily pain measured by the CHQ-PF50 or the SF-36 at 52 weeks compared to baseline. |
| Joint range-of-motion - 52 weeks | 52 weeks | Percentage of subjects who achieve a 5 degree or more improvement in joint range-ot-motion at 52 weeks compared to baseline. |
| Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability | 52 weeks | Percentage of subjects who develop an AE and/or SAE |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORLynda Polgreen, MD
The Lundquist Institute at Harbor-UCLA Medical Center
Outcome results
None listed